Cargando…

PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness

Programmed death ligand-1 (PD-L1), a promising antitumor target, has proven clinical value against many malignancies. However, the PD-L1 content of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and its correlation with clinical outcomes remain unclear. This study aimed to investigate PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Kun, Qu, Yuanyuan, Dai, Bo, Zhao, Jian-Yuan, Gan, Hualei, Shi, Guohai, Zhu, Yiping, Shen, Yijun, Zhu, Yao, Zhang, Hailiang, Ye, Dingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437001/ https://www.ncbi.nlm.nih.gov/pubmed/28522811 http://dx.doi.org/10.1038/s41598-017-02005-7

Ejemplares similares

Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma
por: Qu, Yuanyuan, et al.
Publicado: (2016)

Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population
por: Qu, Yuanyuan, et al.
Publicado: (2016)

Xp11.2 translocation renal cell carcinomas in young adults
por: Xu, Linfeng, et al.
Publicado: (2015)

Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma
por: Lu, Yanwen, et al.
Publicado: (2023)

A new risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults
por: Shi, Qiancheng, et al.
Publicado: (2021)

Clinicopathological features of Xp11.2 translocation renal cell carcinoma
por: Lim, Bumjin, et al.
Publicado: (2015)

Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma
por: Guo, Wei, et al.
Publicado: (2023)

Xp11.2 Translocation Renal Cell Carcinoma Diagnosed by Immunohistochemistry and Cytogenetics
por: Dey, Biswajit, et al.
Publicado: (2016)

Bilateral Xp11.2 translocation renal cell carcinoma: a case report
por: Karashima, Takashi, et al.
Publicado: (2018)

Author Correction: The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma
por: Xu, Fujiang, et al.
Publicado: (2018)

The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma
por: Xu, Fujiang, et al.
Publicado: (2017)

Molecular Heterogeneity of Xp11.2 Translocation Renal Cell Carcinoma: The Correlation Between Split Signal Pattern in FISH and Prognosis
por: Zhu, Yiqi, et al.
Publicado: (2021)

Xp 11.2 translocation renal carcinoma in young adults; recently classified distinct subtype
por: Kmetec, Andrej, et al.
Publicado: (2014)

Xp11.2 Translocation Renal Cell Carcinoma: Clinical Characteristics and Potential Prognostic Predictors
por: Dong, Jie, et al.
Publicado: (2021)

Xp11.2 Translocation Renal Cell Carcinoma: A Rare Renal Cell Carcinoma
por: Kalita, Pranjal, et al.
Publicado: (2023)

Laparoscopic radiofrequency ablation-assisted enucleation of Xp11.2 translocation renal cell carcinoma: A case report
por: XU, LINFENG, et al.
Publicado: (2014)

Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients
por: Agizamhan, Sezim, et al.
Publicado: (2018)

Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion
por: Wang, Zhen, et al.
Publicado: (2017)

Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
por: Ma, Wenliang, et al.
Publicado: (2020)

Rapidly progressing renal cell carcinoma associated with Xp11.2 translocations: a case report
por: Morii, Akihiro, et al.
Publicado: (2012)

Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas
por: He, Jian, et al.
Publicado: (2015)

Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
por: Liu, Ning, et al.
Publicado: (2016)

Gender difference analysis of Xp11.2 translocation renal cell carcinomas’s attack rate: a meta-analysis and systematic review
por: Zhuang, Wenyuan, et al.
Publicado: (2020)

Ultrasonographic Findings of Renal Cell Carcinomas Associated with Xp11.2 Translocation/TFE3 Gene Fusion
por: Ling, Wenwu, et al.
Publicado: (2017)

Percutaneous radiofrequency ablation on a Xp11.2 Translocation Renal Cell Carcinoma: A case report
por: Kanas, Alexandre Fligelman, et al.
Publicado: (2020)

Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China
por: Liu, Ning, et al.
Publicado: (2020)

Contrast‐Enhanced Ultrasound Features of Adult Xp11.2 Translocation Renal Cell Carcinoma: Differential Diagnosis With Three Main Renal Cell Carcinoma Subtypes
por: Ma, Wenliang, et al.
Publicado: (2022)

High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma
por: Cao, Dalong, et al.
Publicado: (2018)

Surgical treatment for Xp11.2 translocation renal cell carcinoma with venous thrombus: A STROBE-compliant study
por: Ge, Liyuan, et al.
Publicado: (2019)

Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide–chlorambucil conjugate
por: Funasaki, Shintaro, et al.
Publicado: (2022)

Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma
por: Cheng, Jun, et al.
Publicado: (2020)

Estradiol increases risk of topoisomerase IIβ-mediated DNA strand breaks to initiate Xp11.2 translocation renal cell carcinoma
por: Shi, Qiancheng, et al.
Publicado: (2021)

Magnetic Resonance Imaging and Computed Tomography Characteristics of Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusion
por: Wang, Wei, et al.
Publicado: (2014)

Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
por: Wu, Junlong, et al.
Publicado: (2017)

Xp11.2 translocation renal cell carcinoma in the autosomal dominant polycystic kidney disease patient with preserved renal function
por: Huh, Hyuk, et al.
Publicado: (2017)

Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas
por: Zhou, Jiale, et al.
Publicado: (2022)

MiT translocation renal cell carcinomas: two subgroups of tumours with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1 or X or 17)]
por: Hora, Milan, et al.
Publicado: (2014)

Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies
por: Cheng, Xiangming, et al.
Publicado: (2016)

Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature
por: Gong, Pengfeng, et al.
Publicado: (2018)

MicroRNA‐204‐5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma
por: Kurahashi, Ryoma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_psmrl74p20tusfjtdqcdtvs9gs